Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Treasury Shares (2022 - 2025)

Maxcyte has reported Treasury Shares over the past 4 years, most recently at $1.8 million for Q4 2025.

  • Quarterly Treasury Shares rose 5.97% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 5.97% year-over-year, with the annual reading at $1.8 million for FY2025, 5.97% up from the prior year.
  • Treasury Shares was $1.8 million for Q4 2025 at Maxcyte, up from $1.7 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $1.8 million in Q4 2025 and troughed at $643600.0 in Q4 2022.
  • The 4-year median for Treasury Shares is $1.5 million (2023), against an average of $1.4 million.
  • Year-over-year, Treasury Shares soared 101.4% in 2023 and then increased 5.97% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $643600.0 in 2022, then skyrocketed by 101.4% to $1.3 million in 2023, then surged by 31.47% to $1.7 million in 2024, then rose by 5.97% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Treasury Shares are $1.8 million (Q4 2025), $1.7 million (Q4 2024), and $1.3 million (Q4 2023).